ArticleFrontiers in medicine2026
Biogenic
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Osteomyelitis is an inflammatory bone disease caused by infectious microorganisms. Challenges in treating chronic osteomyelitis include antibiotic resistance, inadequate immune response, and the need for surgical debridement. As an alternative treatment strategy, we developed a formulation of green phytosynthesized silver nanoparticles (AgNPs) and plant extract, as a novel multifunctional drug to achieve antibacterial and osteogenic activities in osteomyelitis. Methods: Green silver nanoparticles (CS-AgNPs) were successfully phytosynthesized using Results: Functionally, CS-AgNPs, combined with plant extract (CS-AgNPs/PE), exhibited significant antibacterial potency. This hybrid formulation significantly reduced MIC and MBC values against Conclusion: Our data provide a novel green nanoparticles formulation with dual anti-bacterial and osteoinductive actions as a promising therapeutic strategy for chronic osteomyelitis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.